References
- International workshop on Acute Lymphoblastic Leukemia. Assessment of Progress and Future Directions. Venice October, 1987; 28–30
- Herberman R, Holden H. Cell-mediated immunity to tumor cells. Adv Cancer Res 1974; 19: 207–263
- Herberman R. NK Cells and Other Natural Effector Cells. New York 1982; 1–1566
- Ortaldo J, Herberman R. Heterogeneity of natural killer cells. Annu Rev Immunol 1984; 2: 359–384
- Grimm E, Mazumder A, Zhang H, Rosenberg S. Lymphokine-activated killer cell phenomenon I. Lysis of natural killer resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 1823–1827
- Grimm E, Ramsky K, Wilson D, Djeu J, Rosenberg A. Lymphokine-activated killer cell phenomenon II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med 1983; 157: 884–888
- Grimm E, Robb R, Neckers L, Lachman L, Wilson D, Rosenberg S. Lymphokine-activated cell phenomenon III. Evidence that IL-2 is sufficient for direct activation of peripheral lymphocytes into lymphokine-activated killer cells. J Exp Med 1983; 158: 1356–1360
- Grimm E, Wilson D. The human lymphokine-activated killer cell system. Purified recombinant interleukin-2 activates cytotoxic lymphocytes which lyse both natural-resistent autologous and allogeneic tumours and trinitrophenyl-modified autologous peripheral blood lymphocytes. Cell Immunol 1985; 94: 568–572
- Itoh F, Tilden A, Kumagai K, Balch C. Leu 11 + lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL2)-induced activated killer (AK) cells. J Immnol 1985; 134: 802–807
- Ortaldo J, Mason A, Overton R. Lymphokine-activated killer cells. Analysis of progenitors and effectors. J Exp Med 1986; 164: 1193–1198
- Rosenstein M, Yron I, Kaufman Y, Rosenberg S. Lymphokine-activated killer cells: Lysis of fresh syngeneic natural killer resistant murine tumor cells by lymphocytes cultured in interleukin 2. Cancer Res 1984; 44: 1946–1950
- Tanaka Y. Natural killer activity in children with acute lymphoblastic leukemia. Hiroshima J Med Sci 1981; 30: 127–133
- McGeorge M, Russell E, Mohanakumar T. Immunologic evaluation of long term effects of childhood ALL chemotherapy: Analysis of in vitro NK and K activities of peripheral blood lymphocytes. Am J Hematol 1982; 12: 19–27
- Fierro MT, Xin-Sheng L, Lusso P, et al. In vitro and in vivo susceptibility of human leukemic cells to lymphokine-activated killer activity. Leukemia, in press
- Gotoh Y, Minegishi M, Yamaguchi Y, Konno T, Taka K. Interleukin-2 activated peripheral blood lymphocytes and the correlation of lytic activity and peanut agglutinin receptor expression on malignant cells. Clin Exp Immunol 1984; 58: 710–716
- Maccario R, Nespoli L, Mingrat M, Vitiello A, Ugazio AG, Burgio GR. Lymphocyte subpopulation in the neonate: Identification of an immature subset of OKT8-positive, OKT3-negative cells. J Immunol 1983; 130: 1129–1132
- Lotzova E, McCred E, Maroun J, Dicke K, Freireich E. Some studies of natural killer cells in man. Transplant Proc 1979; 11: 1390–1392
- Dobholkar M, Advani S, Tatake R, Gancal S. Natural and antibody-dependent cellular cytotoxicity in chronic myeloid leukemia patients in remission. Leuk Res 1986; 10: 203–209
- Dickinson A, Proctor S, Jacobs E, et al. Natural killer activity in childhood acute lymphoblastic leukemia in remission. Br J Haematol 1985; 59: 45–53
- Yoda Y, Abe T, Tashiro A, et al. Normalized natural killer (NK.) activity in long term remission of acute leukemia. Br J Haematol 1983; 55: 305–309
- Feldman S, Lott L. Varicella in children with cancer: Impact of antiviral therapy and prophylasix. Pediatrics 1987; 80: 465–472
- Oshimi K, Oshimi Y, Akutsu M, et al. Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells. Blood 1986; 4: 938–948